Herceptin Biosimilar for Breast Cancer Now Available in U.S. Market
You may have heard of Herceptin, the targeted treatment for HER2+ breast cancer whose efficacy has truly revolutionized the previously dismal outcome of this subtype. Even though Herceptin is covered by most insurance companies in the United States, this is certainly not the case in all countries and furthermore, this …